Institutional Repository of Vilnius University
Lokalaus priešvėžinio gydymo modeliavimas panaudojant in vitro sistemą, sudarytą iš prostatos vėžio ląstelių DU-145 ir anti-PD-L1 imunomoduliatoriaus atezolizumabo /
Abstract
dc:descriptionAtezolizumab is an anti-PD-L1 monoclonal antibody which targets immunosuppressive PD 1 and PD-L1 axis used by cancer cells to avoid the host immune system and is approved for treatment of several types of cancer. Despite its efficacy in some types of cancer, atezolizumab monotherapy shows limited capabilities in the treatment of prostate cancer. Soluble sPD-(L)1 factors and chemotherapy drugs might possibly dictate atezolizumab effectiveness and an outcome of prostate cancer treatment. The main aim of this thesis is to describe sPD-(L)1 and chemotherapy drugs impact on atezolizumab effectiveness. Goals of the thesis: to assess PD-L1 expression in the prostate cancer cell line DU-145, to evaluate membranous PD-L1 interaction with atezolizumab, to determine preoperative blood serum PD-(L)1 concentrations of prostate cancer patients, to evaluate sPD-(L)1 effect on atezolizumab binding to PD-L1, to assess chemotherapy drugs impact on atezolizumab effectiveness. The flow cytometry approach was used to evaluate atezolizumab binding to membranous PD L1. Atezolizumab binding was measured by fluorescence intensity of prostate cancer cell line DU-145 caused by anti-PD-L1 FITC bound to unoccupied PD-L1 ligands after the effect of soluble sPD-(L)1 or drugs used in chemotherapy. Results show that DU-145 cells are PD-L1 positive and atezolizumab in vitro effectively binds to membranous PD-L1. However, atezolizumab interaction with membranous PD-L1 is suppressed by soluble sPD-L1 and sPD-1 factors found in prostate cancer patient’s blood serum. Furthermore, membranous PD-L1 expression is activated by drugs used in chemotherapy but nonetheless the additional PD-L1 ligands are effectively blocked by atezolizumab. All in all, soluble sPD-(L)1 molecules and PD L1 expression induction chemotherapy drugs should be considered in local anti-cancer therapies based on PD-L1 inhibitors.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Survila, Žilvinas,
Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- lit
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD192979087&prefLang=en_US